Skip header and navigation

3 records – page 1 of 1.

5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

https://arctichealth.org/en/permalink/ahliterature275383
Source
Int J Cancer. 2016 Jun 15;138(12):2820-8
Publication Type
Article
Date
Jun-15-2016
Author
Teemu J Murtola
Elina K Karppa
Kimmo Taari
Kirsi Talala
Teuvo L J Tammela
Anssi Auvinen
Source
Int J Cancer. 2016 Jun 15;138(12):2820-8
Date
Jun-15-2016
Language
English
Publication Type
Article
Keywords
5-alpha Reductase Inhibitors - therapeutic use
Aged
Antineoplastic Agents - therapeutic use
Early Detection of Cancer
Finland - epidemiology
Humans
Kaplan-Meier Estimate
Male
Mass Screening
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Prostatic Neoplasms - diagnosis - drug therapy - mortality
Abstract
Randomized clinical trials have shown that use of 5a-reductase inhibitors (5-ARIs) lowers overall prostate cancer (PCa) risk compared to placebo, while the proportion of Gleason 8-10 tumors is elevated. It is unknown whether this affects PCa-specific survival. We studied disease-specific survival by 5-ARI usage in a cohort of 6,537 prostate cancer cases diagnosed in the Finnish Prostate Cancer Screening Trial and linked to the national prescription database for information on medication use. Cox proportional hazards regression was used to estimate hazard ratios and 95% confidence intervals for prostate cancer-specific deaths. For comparison, survival among alpha-blocker users was also evaluated. During the median follow-up of 7.5 years after diagnosis a total of 2,478 men died; 617 due to prostate cancer and 1,861 due to other causes. The risk of prostate cancer death did not differ between 5-ARI users and nonusers (multivariable adjusted HR 0.94, 95% CI 0.72-1.24 and HR 0.98, 95% CI 0.69-1.41 for usage before and after the diagnosis, respectively). Alpha-blocker usage both before and after diagnosis was associated with increased risk of prostate cancer death (HR 1.29, 95% CI 1.08-1.54 and HR 1.56, 95% CI 1.30-1.86, respectively). The risk increase vanished in long-term alpha-blocker usage. Use of 5-ARIs does not appear to affect prostate cancer mortality when used in management of benign prostatic hyperplasia. Increased risk associated with alpha-blocker usage should prompt further exploration on the prognostic role of lower urinary tract symptoms.
PubMed ID
26804670 View in PubMed
Less detail

[Localized prostatic cancer. Survival and loss of life expectancy]

https://arctichealth.org/en/permalink/ahliterature21502
Source
Ugeskr Laeger. 1998 Jul 27;160(31):4517-20
Publication Type
Article
Date
Jul-27-1998
Author
K. Brasso
S. Friis
K. Juel
T. Jørgensen
P. Iversen
Author Affiliation
H:S Rigshospitalet, kirurgisk afdeling D, Kraeftens Bekaempelse, København.
Source
Ugeskr Laeger. 1998 Jul 27;160(31):4517-20
Date
Jul-27-1998
Language
Danish
Publication Type
Article
Keywords
Aged
Denmark - epidemiology
English Abstract
Humans
Life expectancy
Male
Middle Aged
Prognosis
Prostatic Neoplasms - diagnosis - drug therapy - mortality
Registries
Survival Rate
Abstract
Computerized linkage between the Danish Cancer Registry and the Central Personal Registry was established. A total of 1459 men aged 55-74 years with newly diagnosed clinically localized prostate cancer in the period 1983-1987 were identified. Routine treatment in this period was observation and endocrine therapy in case of progression. Survival analysis demonstrated a significant excess mortality and a substantial loss of life expectancy.
PubMed ID
9700306 View in PubMed
Less detail

Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support.

https://arctichealth.org/en/permalink/ahliterature20472
Source
Prostate. 2000 May 15;43(3):215-22
Publication Type
Article
Date
May-15-2000
Author
F. Labrie
Author Affiliation
Oncology and Molecular Endocrinology Research Center, Department of Medicine, CHUL Research Center, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada. fernand.labrie@crchul.ulaval.ca
Source
Prostate. 2000 May 15;43(3):215-22
Date
May-15-2000
Language
English
Publication Type
Article
Keywords
Androgen Antagonists - therapeutic use
Antineoplastic Agents, Hormonal - therapeutic use
Humans
Male
Mass Screening
Neoplasm Staging
Prospective Studies
Prostatic Neoplasms - diagnosis - drug therapy - mortality - prevention & control
Randomized Controlled Trials
Risk factors
Survival Analysis
Abstract
BACKGROUND: I review the data published during the last 5 years on the effects of early treatment of prostate cancer on survival. METHODS: Data from prospective and randomized studies as well as from population-based studies are presented. RESULTS: Two studies (European Organization for Research and Treatment of Cancer and Radiation Therapy Oncology Group) in stage T3 disease have shown that long-term (3 years or indefinite, respectively) androgen blockade prolongs life in patients receiving androgen blockade in addition to radiotherapy compared to radiotherapy alone. In the UK Medical Research Council study, androgen blockade at diagnosis of locally advanced or asymptomatic patients decreased cancer-specific death by 21% compared to delayed treatment. A 69% decrease in prostate cancer death was observed in the Quebec Randomized Prostate Cancer Screening Study. Population-based studies in Sweden and Denmark have shown that 62% and 63%, respectively, of patients diagnosed with localized prostate cancer will die from the disease if not treated immediately. Decreases in prostate cancer death rate of 6.3-23% have been found between 1991-1997 in the US and Canada, respectively. CONCLUSIONS: Treatment of localized disease has been shown in all the available randomized studies to cause a marked decrease in prostate cancer death. Simple use of the available screening procedures and treatments for localized prostate cancer could cause a dramatic decrease in prostate cancer death.
Notes
Comment In: Prostate. 2000 May 15;43(3):223-410797497
PubMed ID
10797496 View in PubMed
Less detail